Abstract Cyclooxygenase-2, the key player in the biosynthesis of prostaglandin-E2 (PGE2) is often upregulated in colon cancer (CC). TNF-α, the main regulator of COX-2 and mPGES-1, contributes to the increased synthesis of PGE2, which is inhibited by overexpressed prostaglandin dehydrogenase (15-PGDH), a tumor suppressor playing major role in PGE2 catabolism but often downregulated in CC. Interestingly, CC patients expressing high levels of cysteinyl leukotriene receptor-2 (CysLT2R) have good prognosis and therefore, we investigated a potential link between CysLT2R-signaling and 15-PGDH in metastatic CC. Elevation of 15-PGDH expression by LTC4, a CysLT2R ligand, exhibited anti-tumor activity in colon cancer cells with significant phosphorylation of β-catenin with concurrent activation of CASPASE-3 and dramatic down-regulation of TNF-α mRNA expression in two different colon cancer cells. Colony-stimulating factor 1 (CSF-1) is a key regulator of macrophage differentiation that supports the protumorigenic role of tumor-associated macrophages (TAMs). We observed high CSF-1 in metastatic colon cancer with low CysLT2R expression, which is correlated with high level of CD-8+ T-cells and CD-163+ TAMs. CC cell lines produced high amount of CSF-1 when co-cultured with CC-specific CD-8+ T-cell or exposed to T-cell derived cytokines in vitro and exhibited significant reduction with LTC4 stimulation or 15-PGDH overexpression. Furthermore, longer use of 15-PGDH led to downregulation in the PD-L1 in a time-dependent manner. Combination of anti-CSF-1, anti-PD-1 and LTC4 exhibited significant reduction in CC tumor rich in macrophages. Blockade of PD-1/PD-L1 axis also facilitated upregulation of IFN-γ in γδ-T cells. Hence restoration of 15-PGDH expression through CysLT2R-signaling promotes immunomodulatory effect, indicating a promising therapeutic alternative for metastatic CC with high TAM infiltration. Citation Format: Shakti R. Satapathy, Anita Sjolander. Immunomodulatory effect of prostaglandin dehydrogenase in metastatic colon cancer [abstract]. In: Proceedings of the AACR Special Conference on Tumor Immunology and Immunotherapy; 2018 Nov 27-30; Miami Beach, FL. Philadelphia (PA): AACR; Cancer Immunol Res 2020;8(4 Suppl):Abstract nr B53.